We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
- Authors
Fariña-Sarasqueta, Arantza; van Lijnschoten, Gesina; Rutten, Harm J. T.; van den Brule, Adriaan J. C.
- Abstract
Purpose: The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma. Methods: DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping. Results: None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival. Conclusion: In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.
- Subjects
PHARMACOGENOMICS; DRUG therapy; GENETIC polymorphisms; CANCER; MEDICAL research
- Publication
Cancer Chemotherapy & Pharmacology, 2010, Vol 66, Issue 6, p1167
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-010-1403-0